Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

• ClinicalTrials.gov Identifier: NCT02117362
• Recruitment Status: Completed
• First Posted: April 17, 2014
• Last Update Posted: March 21, 2019
• Sponsor: Providence Health & Services
• Collaborators: Providence Cancer Center, Earle A. Chiles Research Institute; Galectin Therapeutics Inc.
• Information provided by (Responsible Party): Providence Health & Services

Study Description

Brief Summary:

The goal of this study is to determine a safe dose of GR-MD-02 used in combination with the FDA-approved dose of ipilimumab (3 mg/kg) in patients who have advanced melanoma. GR-MD-02 is a galectin. Galectins are a family of proteins that have numerous functions in normal mammalian biology including the facilitation of cell-cell interactions, regulation of cell-death and regulation of immune system responses. The hypothesis is that a safe dose of GR-MD-02 when given with the FDA-approved dose of ipilimumab can be found.

Condition or disease	Intervention/treatment	Phase
Metastatic Melanoma	Biological: 1 mg/kg GR-MD-02; Biological: 2 mg/kg GR-MD-02; Biological: 4 mg/kg GR-MD-02; Biological: 8 mg/kg GR-MD-02; Biological: Ipilimumab	Phase 1

Detailed Description:

This study will employ a 3+3 phase I design with dose escalation of GR-MD-02 in conjunction with the standard therapeutic dose of ipilimumab in patients with advanced melanoma for whom ipilimumab would be considered standard of care. In addition to monitoring for toxicity and clinical response, blood samples will be obtained to assess immunologic measures relevant to galectin biology and ipilimumab T-cell check-point inhibition

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 8 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
• Actual Study Start Date: May 8, 2014
• Actual Primary Completion Date: November 28, 2018
• Actual Study Completion Date: November 28, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: Cohort 1; 1 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.	Biological: 1 mg/kg GR-MD-02; 1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.; Other Names: galectin-3 inhibitor; galactoarabino-rhamnogalacturonate; Biological: Ipilimumab; 3 mg/kg ipilimumab on Days 1, 22, 43, and 65; Other Names: Yervoy; Anti-CTLA 4
Experimental: Cohort 2; 2 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.	Biological: 2 mg/kg GR-MD-02; 2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.; Other Names: galectin-3 inhibitor; galactoarabino-rhamnogalacturonate; Biological: Ipilimumab; 3 mg/kg ipilimumab on Days 1, 22, 43, and 65; Other Names: Yervoy; Anti-CTLA 4
Experimental: Cohort 3; 4 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.	Biological: 4 mg/kg GR-MD-02; 4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65; Other Names: galectin-3 inhibitor; galactoarabino-rhamnogalacturonate; Biological: Ipilimumab; 3 mg/kg ipilimumab on Days 1, 22, 43, and 65; Other Names: Yervoy; Anti-CTLA 4
Experimental: Cohort 4; 8 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.	Biological: 8 mg/kg GR-MD-02; 8 mg/mg GR-MD-02; Other Names: galectin-3 inhibitor; galactoarabino-rhamnogalacturonate; Biological: Ipilimumab; 3 mg/kg ipilimumab on Days 1, 22, 43, and 65; Other Names: Yervoy; Anti-CTLA 4

Outcome Measures

Primary Outcome Measures :

1. Determine a safe dose of GR-MD-02 used in combination with the approved dose of ipilimumab (3 mg/kg) [ Time Frame: 21 Days ]
   Patients return to clinic 9 times in 85 days, receiving treatment on Days 1, 22, 43, and 65. Patients will have physical exams, blood tests, and toxicity evaluations by a research nurse during this time to identify any protocol-defined dose limiting toxicity.

Secondary Outcome Measures :

1. Response rate to combined therapy [ Time Frame: 85 Days ]
   Tumor burden assessments will occur at screening, Day 85, and every 12 weeks thereafter to determine the response rate.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients with metastatic or unresectable melanoma for whom treatment with ipilimumab is indicated. Histological confirmation of melanoma will be required by previous biopsy or cytology.
• Patients must be ≥ 18 years of age.
• Eastern Collaborative Oncology Group (ECOG) performance status of 0-1.
• Women of childbearing potential must have a serum or urine pregnancy test performed within 72 hours prior to the start of protocol treatment. The results of this test must be negative in order for the patient to be eligible. In addition, women of childbearing potential as well as male patients must agree to take appropriate precautions to avoid pregnancy.
• No active bleeding.
• Anticipated lifespan greater than 12 weeks.
• Patients must sign a study-specific consent document.

Exclusion Criteria:

• Patients who have previously received a galectin antagonist
• Prior ipilimumab to treat metastatic melanoma (prior ipilimumab in the adjuvant setting is permitted if the patient did not experience ≥ grade 3 toxicity related to immunotherapy.
• Patients with active autoimmune disease except for autoimmune thyroiditis or vitiligo.
• Patients with history of colitis
• Patients with untreated brain metastases. Patients with treated brain metastases who demonstrate control of brain metastases with follow-up imaging 4 or more weeks after initial therapy are eligible.
• Other active metastatic cancer requiring treatment.
• Patients with active infection requiring antibiotics.
• Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.
• Laboratory exclusions (to be performed within 28 days of enrollment):
• Need for chronic steroids. Inhaled corticosteroids are acceptable.
• Inability to give informed consent and comply with the protocol. Patients with a history of psychiatric illness must be judged able to understand fully the investigational nature of the study and the risks associated with the therapy.
• Any medical condition that in the opinion of the Principal Investigator would compromise the safety or conduct of the study procedures.

Contacts and Locations

Locations

United States, Oregon

Providence Portland Medical Center

Portland, Oregon, United States, 97213

Sponsors and Collaborators

Providence Health & Services

Providence Cancer Center, Earle A. Chiles Research Institute

Galectin Therapeutics Inc.

Investigators

• Principal Investigator: Brendan Curti, MD; Providence Health & Services

More Information

Additional Information:

Providence Cancer Center 

• Responsible Party: Providence Health & Services
• ClinicalTrials.gov Identifier: NCT02117362
• Other Study ID Numbers: 14-004A
• First Posted: April 17, 2014
• Last Update Posted: March 21, 2019
• Last Verified: April 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Providence Health & Services:

GR-MD-02; Melanoma; Ipilimumab; Yervoy; Galectin; galactoarabino-rhamnogalacturonate; galectin-3 inhibitor; Providence Health & Services; Earle A. Chiles Research Institute; Robert W. Franz Cancer Center; Immunotherapy

Additional relevant MeSH terms:

Melanoma; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Ipilimumab; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immune Checkpoint Inhibitors; Molecular Mechanisms of Pharmacological Action